inVentiv Health Selects Medidata Enroll®, Medidata’s eConsent Platform, to Accelerate Clinical Trials
June 26 2017 - 8:30AM
Business Wire
inVentiv and Medidata Partner to Expand Use
of Patient-Centered Technology to Better Connect Patients, Sites
and Biopharmaceutical Clients
Medidata (NASDAQ:MDSO), the leading global provider of
cloud-based technology and data analytics for clinical research,
and inVentiv Health, a leading biopharmaceutical professional
services company, today announced a multi-year partnership to bring
patient-centric technology and leading clinical trial expertise to
the biopharmaceutical industry. The partnership will broaden the
reach of Medidata’s industry-leading electronic informed consent
(eConsent) technology, Medidata Enroll, to patients, sites and
biopharmaceutical clients worldwide.
Medidata recently acquired Mytrus, Incorporated, an eClinical
technology company specializing in eConsent and virtual trials.
inVentiv, an early adopter of eConsent technology, invested in
Mytrus in 2013. inVentiv and Medidata will now partner to provide
their joint customers with best-in-class training, services and
support around the use of the advanced eConsent platform, Medidata
Enroll.
“As clinical development evolves toward a more patient-centric,
technologically-savvy model, the use of eConsent is becoming
increasingly relevant,” said Rachel Stahler, Chief Information
Officer, inVentiv Health. “By pairing Medidata’s industry-leading
technology platform with inVentiv’s vast clinical trial and patient
engagement capabilities, we can expedite study start-up and
transform the trial process for patients and sites. This
partnership reinforces our commitment to delivering better systems,
rich data and actionable insights to accelerate our clients’
abilities to deliver important therapies to market.”
A critical component to any clinical trial, electronic informed
consent provides patients with clear, visually compelling
information about trial participation in an easily accessible
digital format. This modernized process facilitates dialogue
between physician and patient, and may increase patient engagement
in a trial. Medidata Enroll also provides advanced visualization
and analytics for trial sponsors and monitors, and streamlines site
workflow and data capture.
“CROs are critical partners in delivering transformative
technology like eConsent to our clients in clinical development,”
said Kara Dennis, Medidata’s managing director of mHealth. “We’re
thrilled to see inVentiv Health show leadership in this area by
broadly adopting Medidata Enroll across its clinical development
programs. Medidata is committed to designing, building and
supporting patient-centric tools to capture important data and
facilitate meaningful dialogue between researchers and patients,
and we look forward to combining our technology with inVentiv’s
globally-recognized expertise to pioneer a more efficient consent
process.”
Together, Medidata and inVentiv Health are facilitating an
updated trial experience, enabling biopharmaceutical companies,
sites and patients to make use of Medidata’s intuitive technology
to better support trial operations and virtual patient engagement.
With inVentiv Health’s ability to support clients in 90
countries—having developed or commercialized 82% of novel new drugs
approved by the FDA in the last five years—the strategic
partnership is also expanding Medidata’s reach to sponsors all over
the globe.
About inVentiv Health
inVentiv Health is a global professional services organization
designed to help the biopharmaceutical industry accelerate the
delivery of much-needed therapies to market. Our combined Clinical
Research Organization (CRO) and Contract Commercial Organization
(CCO) offer a differentiated suite of services, processes and
integrated solutions that improve client performance. With more
than 15,000 employees and the ability to support clients in more
than 90 countries, our global scale and deep therapeutic expertise
enable inVentiv to help clients successfully navigate an
increasingly complex environment. For more information, visit
inVentivHealth.com.
About Medidata
Medidata is reinventing global drug and medical device
development by creating the industry's leading cloud-based
solutions for clinical research. Through our advanced applications
and intelligent data analytics, Medidata helps advance the
scientific goals of life sciences customers worldwide, including
over 850 global pharmaceutical companies, biotech, diagnostic and
device firms, leading academic medical centers, and contract
research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled
clinical trial data assets provide deep insights that pave the way
for future growth. The Medidata Clinical Cloud is the primary
technology solution powering clinical trials for 18 of the world's
top 25 global pharmaceutical companies and is used by 18 of the top
25 medical device developers—from study design and planning through
execution, management and reporting.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170626005366/en/
Medidata SolutionsInvestors:Anthony D’Amico, +1
732-767-4331adamico@mdsol.comorMedia:Erik Snider, +1
646-362-2997esnider@mdsol.comorinVentiv HealthDanielle
DeForge, +1 202 210 5992danielle.deforge@inventivhealth.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024